KIR3DL1 and acute myeloid leukemia: Hematopoietic cell transplantation from KIR–HLA-mismatched donors is associated with a marked event-free survival benefit in patients with AML [2–4], but the benefit of NK cell infusion as a consolidation therapy remains unclear for children with AML.